PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12481411-0 2002 Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Doxorubicin 124-135 plasminogen Homo sapiens 106-113 12481411-8 2002 The synthesized construct also possessed plasmin substrate properties as demonstrated by doxorubicin release from 1 upon incubation with plasmin. Doxorubicin 89-100 plasminogen Homo sapiens 41-48 14734647-0 2004 Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity. Doxorubicin 18-29 plasminogen Homo sapiens 0-7 14734647-1 2004 To generate doxorubicin (Dox) specifically at the tumor site, the chemotherapeutic agent was incorporated into a prodrug by linkage to a peptide specifically recognized by plasmin, which is overproduced in many cancers. Doxorubicin 12-23 plasminogen Homo sapiens 172-179 14734647-1 2004 To generate doxorubicin (Dox) specifically at the tumor site, the chemotherapeutic agent was incorporated into a prodrug by linkage to a peptide specifically recognized by plasmin, which is overproduced in many cancers. Doxorubicin 25-28 plasminogen Homo sapiens 172-179 11934232-3 2002 Antagonist G-targeted liposomes (PLG) were prepared and loaded with doxorubicin and their cellular association and cytotoxicity were evaluated using the human small cell lung cancer H69 cell line. Doxorubicin 68-79 plasminogen Homo sapiens 33-36 12481411-8 2002 The synthesized construct also possessed plasmin substrate properties as demonstrated by doxorubicin release from 1 upon incubation with plasmin. Doxorubicin 89-100 plasminogen Homo sapiens 137-144 10602713-1 1999 New prodrugs of daunorubicin and doxorubicin designed for selective activation by the serine protease plasmin are described. Doxorubicin 33-44 plasminogen Homo sapiens 102-109 11749612-7 2001 Prodrugs in which the novel spacer systems were incorporated between a specific tripeptide specifier and the parent drug doxorubicin or paclitaxel proved to be significantly faster activated by plasmin in comparison with prodrugs containing conventional spacer systems. Doxorubicin 121-132 plasminogen Homo sapiens 194-201 10602713-6 1999 A marked in vitro selectivity was demonstrated by incubation of the doxorubicin prodrugs with a plasmin generating MCF-7 breast cancer cell line transfected with urokinase-type plasminogen activator (u-PA) in comparison with the nontransfected nonplasmin generating cell line. Doxorubicin 68-79 plasminogen Homo sapiens 96-103 10602713-7 1999 Prodrugs 4 and 5 showed the same cytotoxic effect as the free parent drug doxorubicin in the u-PA transfected cells, indicating complete conversion of the prodrug by plasmin. Doxorubicin 74-85 plasminogen Homo sapiens 166-173 24905776-0 2014 A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation. Doxorubicin 72-83 plasminogen Homo sapiens 56-59 6302253-3 1983 We have synthesized peptidyl prodrugs of doxorubicin (Dox) designed to be selective substrates of plasmin. Doxorubicin 41-52 plasminogen Homo sapiens 98-105 6302253-3 1983 We have synthesized peptidyl prodrugs of doxorubicin (Dox) designed to be selective substrates of plasmin. Doxorubicin 54-57 plasminogen Homo sapiens 98-105 6302253-9 1983 These results demonstrate that peptidyl prodrugs of doxorubicin designed as plasmin substrates are more selective anticancer agents in vitro than doxorubicin itself but that the bulky anthracycline moiety probably prevents efficient plasmin-catalyzed conversion to the active parent drug, so that, in their present form, these drugs are not potent enough to allow a determination as to whether or not they are more selective in vivo. Doxorubicin 52-63 plasminogen Homo sapiens 76-83 6302253-9 1983 These results demonstrate that peptidyl prodrugs of doxorubicin designed as plasmin substrates are more selective anticancer agents in vitro than doxorubicin itself but that the bulky anthracycline moiety probably prevents efficient plasmin-catalyzed conversion to the active parent drug, so that, in their present form, these drugs are not potent enough to allow a determination as to whether or not they are more selective in vivo. Doxorubicin 52-63 plasminogen Homo sapiens 233-240 29878753-4 2018 The enzymatic release of doxorubicin from the prodrugs by both protease (plasmin) and human carboxylesterases (hCE1 and 2) was demonstrated in vitro and the cytotoxic effect of the prodrugs was assayed on MCF-7 breast cancer cells. Doxorubicin 25-36 plasminogen Homo sapiens 73-80 24905776-3 2014 DOX HCl was encapsulated via electrostatic interaction and hydrophobic stack between the DOX HCl and mPEG-b-PLG-g-PTX in aqueous solution. Doxorubicin 0-7 plasminogen Homo sapiens 108-111 24905776-4 2014 The release rate of DOX HCl from the drug-loaded nanoparticles (mPEG-b-PLG-g-PTX-DOX) was slow at blood pH (pH 7.4), but obviously increased at endosome pH (pH 5.4). Doxorubicin 20-27 plasminogen Homo sapiens 71-74 32329202-8 2020 In vitro cytotoxicity assay indicates that DOX loaded mixture nanoparticles (ratio of PLL-MSN to PLG-MSN is 1:1) can be triggered for drug release in HeLa cells, resulting in 88% of cell killing. Doxorubicin 43-46 plasminogen Homo sapiens 97-100 24905776-6 2014 For in vivo treatment of xenograft human breast tumor (MCF-7), the mPEG-b-PLG-g-PTX-DOX nanoparticles exhibited remarkable tumor inhibition effect with a 95.5% tumor-suppression-rate which was significantly higher than those of related single anticancer agents such as free DOX HCl and mPEG-b-PLG-g-PTX. Doxorubicin 84-87 plasminogen Homo sapiens 74-77 24905776-1 2014 Herein, we develop a co-delivery system of paclitaxel (PTX) and doxorubicin hydrochloride (DOX HCl) based on methoxypoly(ethylene glycol)-block-poly(L-glutamic acid) (mPEG-b-PLG) for cancer treatment. Doxorubicin 64-89 plasminogen Homo sapiens 174-177 24905776-6 2014 For in vivo treatment of xenograft human breast tumor (MCF-7), the mPEG-b-PLG-g-PTX-DOX nanoparticles exhibited remarkable tumor inhibition effect with a 95.5% tumor-suppression-rate which was significantly higher than those of related single anticancer agents such as free DOX HCl and mPEG-b-PLG-g-PTX. Doxorubicin 84-87 plasminogen Homo sapiens 293-296 24905776-6 2014 For in vivo treatment of xenograft human breast tumor (MCF-7), the mPEG-b-PLG-g-PTX-DOX nanoparticles exhibited remarkable tumor inhibition effect with a 95.5% tumor-suppression-rate which was significantly higher than those of related single anticancer agents such as free DOX HCl and mPEG-b-PLG-g-PTX. Doxorubicin 274-281 plasminogen Homo sapiens 74-77 24905776-1 2014 Herein, we develop a co-delivery system of paclitaxel (PTX) and doxorubicin hydrochloride (DOX HCl) based on methoxypoly(ethylene glycol)-block-poly(L-glutamic acid) (mPEG-b-PLG) for cancer treatment. Doxorubicin 91-94 plasminogen Homo sapiens 174-177 22281424-3 2012 The anti-cancer drug, doxorubicin (DOX) was covalently conjugated onto the hydrophobic segments of the amphiphilic block copolymer arms (i.e., PLG) via a pH-labile hydrazone linkage to enable pH-controlled drug release. Doxorubicin 22-33 plasminogen Homo sapiens 143-146 22281424-3 2012 The anti-cancer drug, doxorubicin (DOX) was covalently conjugated onto the hydrophobic segments of the amphiphilic block copolymer arms (i.e., PLG) via a pH-labile hydrazone linkage to enable pH-controlled drug release. Doxorubicin 35-38 plasminogen Homo sapiens 143-146